Tilray® Imports GMP-Certified Standardized Medical Cannabis Oil Into Ireland
11 July 2019 - 4:00PM
Business Wire
Ireland becomes the 13th country with Tilray medical cannabis
products as company continues global expansion in Europe and
increases access to patients in need
Tilray Inc. (TLRY:NASDAQ), a global pioneer in cannabis
cultivation, processing and distribution, today announced that it
has successfully imported Good Manufacturing Practices
(GMP)-certified finished medical cannabis oral solutions into
Ireland intended for nationwide distribution.
On June 26, 2019, Ireland’s Department of Health enacted the
Medical Cannabis Access Programme, which provides compassionate
access to medical cannabis for patients in need in Ireland. This
new program provides an alternative to legislation that only allows
access by patients with a ministerial license, marking a
significant milestone for Ireland and the global medical cannabis
industry. The Medical Cannabis Access Programme is expected to
allow patients to access Tilray oral solutions in the second half
of this year. Patients suffering from indications not covered by
the program will still have the option to obtain a ministerial
license for such products.
“This development in Ireland represents an exciting turning
point for patients,” says Catherine Jacobson, Tilray’s Vice
President of Medical and Regulatory Affairs. “We’re proud to have
the opportunity to provide patients in Ireland with access to
Tilray’s standardized GMP-certified medical cannabis products, and
we’re thrilled to see an increasing number of countries improve
access to medical cannabis. We will continue to do our part to
increase access for patients in need around the world.”
The Tilray products successfully imported will be made available
to qualified patients through the Access Programme once
distribution approvals are provided by local regulators. This will
allow patients in Ireland access to a locally maintained supply of
GMP-certified products, which they can receive in a reasonable
time-frame. Authorized patients are expected to be able to access
Tilray medical cannabis products through the Irish community
pharmacy network in the second half of the year.
“We’re proud to celebrate the milestone of Ireland becoming the
13th country to receive Tilray products,” says Sascha Mielcarek,
Tilray’s Managing Director, Europe. “As we continue our expansion
in Europe and around the world, it’s encouraging to see regulators’
commitment to quality and safety. We look forward to supplying
patients in Ireland with our full offering of pharmaceutical-grade
medical cannabis products as regulations allow.”
The products imported into Ireland are GMP-manufactured oral
solutions containing tetrahydrocannabinol (THC) and cannabidiol
(CBD). Such products will be used to treat approved indications in
Ireland, as regulations allow. Tilray intends to supply Irish
patients with its full suite of medical cannabis products when
authorized by the country’s Department of Health.
About Tilray®
Tilray is a global pioneer in cannabis cultivation, processing
and distribution currently serving tens of thousands of patients in
13 countries spanning five continents.
Cautionary note regarding forward-looking statements:
This press release contains “forward-looking statements” within
the meaning of the U.S. Private Securities Litigation Reform Act of
1995 and “forward-looking information” within the meaning of
Canadian securities laws, or collectively, forward-looking
statements. Forward-looking statements or
forward-looking-information in this press release may be identified
by the use of words such as, “may”, “would”, “could”, “will”,
“likely”, “expect”, “anticipate”, “believe, “intend”, “plan”,
“forecast”, “project”, “estimate”, “outlook” and other similar
expressions, including without limitation statements in respect to
Tilray’s intention to make products available in new or existing
markets. Forward-looking statements are not a guarantee of future
performance and are based upon a number of estimates and
assumptions of management in light of management’s experience and
perception of trends, current conditions and expected developments,
as well as other factors that management believes to be relevant
and reasonable in the circumstances, including assumptions in
respect of current and future market conditions, the current and
future regulatory environment and future approvals and permits.
Actual results, performance or achievement could differ materially
from that expressed in, or implied by, any forward-looking
statements in this press release, and, accordingly, you should not
place undue reliance on any such forward-looking statements and
they are not guarantees of future results. Please see the heading
“Risk Factors” in Tilray’s Quarterly Report on Form 10-Q, which was
filed with the Securities and Exchange Commission and Canadian
securities regulators on May 15, 2019, assumptions, uncertainties
and other factors that may cause actual future results or
anticipated events to differ materially from those expressed or
implied in any forward-looking statements. Tilray does not
undertake and specifically declines any obligation to update any
forward-looking statements that are included herein, except in
accordance with applicable securities laws.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190710005903/en/
Media, Global: Chrissy Roebuck, +1-833-206-8161, news@tilray.com
Investors: Katie Turner, +1-646-277-1228,
Katie.turner@icrinc.com
Tilray Brands (NASDAQ:TLRY)
Historical Stock Chart
From Apr 2024 to May 2024
Tilray Brands (NASDAQ:TLRY)
Historical Stock Chart
From May 2023 to May 2024